We’re used to seeing biotech stocks surge because of the results of a clinical trial… but it’s quite crazy to see the whole market pinning its hopes on a clinical trial. Gilead’s (GILD) Remdisivir had some weak results leak last week and that helped inspire the market selloff (“Oh no, we won’t get a drug […]
Articles
I shared a brief Trade Note yesterday about the sale of part of my position in Innovative Industrial Properties (IIPR), and I promised to go much more in depth in my thinking today… so strap yourself in. (And if you don’t care about IIPR at all or aren’t interested in “bear attacks”, you can skip […]
It’s been an unusually active month in the Real Money Portfolio — a couple big sells, several brand new positions, and quite a bit more churn than I usually have. Those transactions have mostly been fairly small, the largest position that I opened or closed was the sale of my sub-2% Facebook position, but that’s […]
The competition for your brokerage account has gotten fierce again, which is great news for investors. There’s no longer any reason to pay brokerage commissions for buying or selling stock… which makes it so much easier for small individual shareholders to be slow and gradual in their portfolio-building, and I think that’s great — don’t […]
Gold had its worst day yesterday since 2016, so that was a little shock to the system — mostly, I think, because the latest leaks and Tweets about the China trade dispute were relatively optimistic, with meetings scheduled for next month. It’s hard to imagine we’re going to have a “real” trade deal before the […]
Thanks for your kind wishes (and patience) as I took a couple weeks off with my family — we had a wonderful and relaxing getaway in a few of the jewels of the Rocky Mountains as we toured through some northern national parks, most of them blessedly devoid of cell phone service or wifi, but […]
Indulge me for a moment, dear reader — I’m going to wander around thinking about valuation and about short selling, then get into talking about a current situation that closely mirrors some of the long/short pairs trades I’ve done in the past year or so. Then we’ll talk some about gold, since that seems to […]
There’s no more cyclical stock than a semiconductor stock, and we’re seeing the whipsaw slash through that market now as trade sentiment weakens and pundits begin to see some weakness in the economy, particularly in the employment numbers, and the Federal Reserve fuels that uncertainty by essentially promising a rate cut in their attempt to […]
So… anything happen this week? 🙂 We’ll start with a few headline-grabbers from the Real Money Portfolio in the technology world, slide into a little teaser solution for you, and then share some updates on a couple small buys I made, plus some additions to the watchlist, along with the usual blather… Xilinx (XLNX) had […]
A happy Friday to all of you out there in Gumshoeland… I’ve got a bunch of little stories to cover, starting with a chain of thoughts about some of the overvalued “cloud” stocks that have generated a little news in recent days, and then I’ll provide a few updates on other stocks, and a couple […]
As we close in on the end of the first quarter, it’s time to release some more data — I just posted the 2019 teaser tracking spreadsheet for you, you can find it on the tracking page along with all our previous years and use it both to see what we’ve been covering so far […]
It seems we’ve officially entered a period of another “Fed Put” — Fed Chair Jerome Powell’s statements yesterday were widely interpreted to mean that there will be no interest rate hikes this year, or maybe ever again, and that the Fed will stop its “quantitative tightening” in six months or so, leaving a huge and […]
I haven’t written about closed-end funds in a while, so when I was skimming through the possible teaser pitches I might cover today this one caught my eye. It’s for Sovereign Man’s 4th Pillar newsletter, helmed by Tim Staermose (it’s pricey at $1,995/year but does, at least, offer a 30-day money-back refund, something most of […]
Heydy ho, investing friends! I finally wrap up my Annual Review this week by covering the final three names… and I’ve also got a bunch of other updates to share with you, along with one add-on buy and one brand-new holding for the Real Money Portfolio… enjoy! We’ll start with the completion of the annual […]
Time, once again, for the Annual Review of all of the stocks I hold in the Real Money Portfolio. Many of my positions are built up over many years, and sometimes they’re stocks that don’t generate a lot of news or attention for months at a time, so I promise each January to cover every […]
A fantastic market last week, a terrible market this week… it’s time, once again for another episode of “Turn Off CNBC and Have Some Perspective!” I won’t go into a long screed about long-term investing here, but I thought I’d just share one of my favorite charts — I see someone post something like this […]
There was an election on Tuesday, I hear. I voted. The counting is almost over now. Apparently the world did not end, and now we begin the campaign for the next election… everyone raise their hand who wants to vote for austerity and deficit reduction and lower spending and higher taxes and delayed Social Security […]
While we wait to see what Berkshire Hathaway’s quarter looked like, how’s the rest of the portfolio holding up? Holy Cow, Starbucks (SBUX)! Haven’t seen that stock take this big of a pop after earnings in a long time, and sentiment seems to have changed so quickly to a “this is a safe capital return […]
If you’re wondering whether it’s interest rates or just “worry about overvaluation or growth” that’s making the stock market go crazy this week, or whether it’s the trade war or political upheaval or something else, well, join the club. There’s some indication that traders are in fear of the “slowdown” that could be caused by […]
A few purchases to talk to you about today, and a couple other notes as we go… mostly on the theme of risk and safety, as we close out a week with lots of news-driven volatility. Ready? Innovative Industrial Properties (IIPR) is, in some ways, a fun way to “play” the marijuana boom with less […]
Before you get sucked into reading more of my blather, take a moment and read the Wall Street Journal if you’ve got a copy nearby or an online subscription — not the whole thing, but read Christopher Mims’ column The World Isn’t as Bad as Your Wired Brain Tells You. It’s an unusually brief and […]
Crazy earnings week, eh? That leads me to a few adjustments to the portfolio, as my opinions have changed about a few stocks at the top of the Real Money Portfolio. So this week your Friday File is another run through a hodgepodge of stocks, starting with the one that I think is looking most […]
Hello, dear friends — I have a few portfolio updates to start with as I get you updated on a few trades that triggered since I last wrote, so adjustments to the portfolio (including a few buys and sells) will be the focus of today’s Friday File. The latest update to the Real Money Portfolio […]
This counts as a “holy crap!” week when it comes to earnings, not because of any huge reporting that moved the market but because of the surge by just one stock, our fad retailer Five Below (FIVE) after earnings on Wednesday night. FIVE is generally lumped into the “dollar store” category, it’s the teen-focused retailer […]
So… what’s going in in the Real Money Portfolio this week, as we close up shop and get ready for a bit of time with family and friends? I do have one buy to share with you today, I decided to pick up some shares of the stock that I wrote to you about a […]
When looking into “buy the correction” ideas, a key problem is getting your head around when a stock has finally “blown off” any excess valuation — fundamentals aren’t falling for most stocks, at least not for the stronger, growth-oriented names in the market, but the stocks are falling anyway… why? Well, obviously we have the […]
This article was originally published in late January — Andy Obermueller is teasing Apple suppliers again, hinting that the Apple “Growth Window” will close up on September 30 (presumably when we start freaking out about their next wave of iPhones and iPads, usually introduced around then), and the descriptions of the teased stocks that he […]
The folks at Street Authority are big fans of the “list of great stocks” teasers — they pitch the idea of a list of blue chippers that are either the top ten picks for this year, or the top ten “forever” buy and hold stocks, give one or two of them away to whet your […]
That “top stock” headline is the promise of Ian Wyatt, not myself, just to be clear. Wyatt and Taylor Laundon put out a letter called Top Stock Insights, the text of the ad for that letter says it’s from Taylor and the letter is “signed” by Ian Wyatt, so I guess we’ll assume it’s a […]
Dozens of folks have been asking me about this latest teaser for “Motley Fool One”, which is yet another Motley Fool service that aims to upgrade folks’ relationship with the Fool — they’ve progressed to running “real money” portfolios in recent years, investing the Fool’s own corporate portfolio, and having more interactive stuff like the […]
Paul Tracy is out again with a similar ad to one he shared a year ago, teasing his top ten stocks for next year — and, like last year, there’s a lot of interest among the Gumshoe readership … so let’s see if we can name those hinted-at picks for you. The basic idea is […]
The folks at StreetAuthority delight in lists of “bests” — best stocks for 2011, best stocks for 2012, best stocks to hold forever, we’ve looked at several of them over the years. And now, what we’re being teased with by these folks are “WGB” investments … which, in case you don’t have the patience to […]
Whole Foods Market, which has been pushed by the Motley Fool Stock Advisor as their favorite pick, and as the “New American Super Brand” for as long as I can remember (when I wrote about this ad over a year ago the first instance of it I could find was from December 2006, when the […]
Hello out there, happy investors of Gumshoe Land! For your pleasure this weekend I thought I’d revisit a couple old teasers that have been making the rounds again, since the emails about them have been piling up and, in some cases, the companies may have gotten more or less interesting. The first one is the […]
This one was recently forwarded by a reader, with a tip as to the company he thought it was (he was right, too). And this is actually a company I owned a few years ago around their IPO, so this is also a nice bitter reminder that I shouldn’t have sold it. The ad is […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
$BIOC Biocept Announces Pricing of $10.0 Million Underwritten Public Offering https://prnewswire.com/news-releases/bioc...
$BIOC sold The USPTO issues U.S. Patent No. 9,834,817 to Biocept (BIOC +12.5%) covering methods of detecting nucleic ...
Looks like a nice hire for Biocept (BIOC). I still think liquid biopsy is the wave for the future and Biocept has the go...
Good Biocept (BIOC) related article. NP https://www.statnews.com/2017/10/12/retinoblastoma-liquid-biopsy/?utm_source=ST...
Biocept (BIOC) added to Russell Microcap Index. https://finance.yahoo.com/news/biocept-added-russell-microcap-index-12...
2017 Catalysts for August - September: Portola $PTLA (fp) Possible Betrixiban launch Biocept $BIOC (sp) Sales growth ...
$BIOC long - found this on twitter from yesterday: Marc Lehman @markflowchatter Jan 12 Biocept $BIOC has a 9 Mil...
Biocept (BIOC) with a impressive abstract. https://cslide.ctimeetingtech.com/library/esmo/browse/search/Mqr#2z94Y0UG ...
Biocept (BIOC) with a nice partnership with Dr. Gupta. http://finance.yahoo.com/news/biocept-collaborate-renowned-cli...
Long Biocept, BIOC. They sent out a notice of an online shareholder proxy vote to determine if there is shareholder supp...
Biocept (BIOC) mentioned in this article. medicalxpress.com/news/2016-06-liquid-biopsy-techniques-edge-cancer(dot)ht...
Biocept (BIOC) a Gummdom moldy oldie, but one I did quite well with in guessing correctly the reaction to the offering ...
Interesting take on Biocept (BIOC). http://247wallst.com/healthcare-business/2015/02/26/has-biocept-reached-an-inflecti...
Logging in after a hiatus. Thanks Elliot for the info on Biotime. Mention is made in the article in SA that you brought ...
Someone was asking above if I had updated thoughts about Biocept (BIOC). Certainly in the recent short-term it has not p...
Biocept (BIOC) up nearly 14 per cent today. No news. Volume heavier than usual, but not heavy....